ANI Pharmaceuticals (ANIP) Q3 2026 earnings review
ANI raises profit targets, but cuts its flagship drug plan
ANI Pharmaceuticals, a maker of rare-disease and generic medicines, raised its full-year profit plan even as pharmacy bottlenecks slowed its flagship drug. Total revenue rose 28% from a year ago to $291 million as generic drugs and sleep-drug royalties offset a third-quarter miss on Cortrophin Gel. Chief executive Nikhil Lalwani also announced a $560 million cash offer to buy Swedish rare-disease drugmaker Egetis Therapeutics.
| Revenue | $290.8M +27.6% from a year ago |
|---|---|
| Cortrophin Gel revenue | $138.7M +36.1% from a year ago; missed $143–153M plan |
| Profit per share, excluding one-offs | $2.70 +32.4% from a year ago |
| Full-year Cortrophin Gel outlook | Cut $40M middle of the range: $490M (+40.9% growth) |
⚖️ Verdict: 🔴 Bearish
The story got worse because ANI had to cut its full-year Cortrophin Gel outlook for a second straight quarter, this time by $40 million. While gout prescriptions doubled from the second quarter, specialty pharmacy bottlenecks prevented those prescriptions from turning into sales, and the new Egetis acquisition will reduce profit per share excluding one-offs in its first year. On the positive side, generic drug launches and high-margin royalties lifted gross margin and allowed management to raise full-year profit targets.
The question now is whether Cortrophin Gel's shortfall is a temporary pharmacy bottleneck or proof that acute gout patients generate much less revenue per prescription. If adding pharmacies clears the backlog, fourth-quarter Cortrophin sales will jump 15% from the third quarter to hit the $159 million middle of the implied plan; if gout prescriptions carry smaller orders, the drug will miss again. Fourth-quarter Cortrophin revenue will settle it.
🐂 Bull Case
Generics and Royalties Carry the Profit Plan
ANI's older businesses and licensing deals paid for the cut to its main rare-disease drug this quarter. Generic drug sales rose 10.7% from a year ago to $104.5 million, driven by "strong market demand for our existing products and new product launches in 2025 and 2026". Meanwhile, the Harmony Biosciences licensing agreement for pitolisant, a sleep-disorder medicine, added $11.5 million in high-margin royalties and milestone payments.
- Implied full-year revenue outside Cortrophin Gel: up $35 million at the middle of the range, to $615 million by our math
- New generic products launched this year: 16, passing the full-year goal of at least 15
- Gross margin excluding one-offs: 61.8%, up 2.6 percentage points as cost of sales fell from 40.8% of revenue to 38.2%
- Third-quarter Harmony revenue: $9.5 million in royalties plus the final $2.0 million development milestone
Because royalty revenue carries almost no production cost, it lifted gross margin and allowed chief executive Nikhil Lalwani to raise the full-year profit outlook even while cutting Cortrophin Gel by $40 million. Without the Harmony agreement, third-quarter revenue grew 22.6% and gross margin excluding one-offs was 60.3% by our math.
What to watch: fourth-quarter generic revenue and pitolisant royalties once milestone payments end. Those two lines must hold their third-quarter run rate when $25 million of first-half and third-quarter upfront and milestone fees do not repeat in 2027.
ILUVIEN Rebounds With Two-Year Eye Data
ILUVIEN, an eye implant for diabetic macular edema and chronic eye inflammation, returned to growth after falling 16.1% last quarter. Third-quarter revenue rose 34.1% from a year ago to $22.3 million on "increased volumes and phasing of international shipments". Finance chief Stephen Carey raised the full-year ILUVIEN outlook by $2 million to $80–85 million.
In October, the drugmaker also presented two-year clinical trial data at the American Academy of Ophthalmology conference, meeting its commitment from last quarter. In that trial, 79.6% of treated eyes had no return of inflammation over 24 months, giving sales reps clinical evidence to pitch retina specialists despite ongoing Medicare patient-assistance funding limits.
What to watch: fourth-quarter ILUVIEN revenue against the $22.3 million implied by the middle of the full-year outlook. Holding that level without international shipment timing benefits would show US doctor adoption is rising on its own.
Egetis Bid Expands Rare Disease With Debt
ANI wants rare-disease medicines to drive its future, while sceptics worry about taking on debt and execution risk for an early launch. On November 5, the company offered $560 million in cash for Swedish drugmaker Egetis Therapeutics, "expanding the scope and scale of ANI’s Rare Disease business". After Egetis sells a regulatory voucher for $190 million gross, the net enterprise price is about $434 million.
The deal adds EMCITATE, the only FDA-approved treatment for MCT8 deficiency, a rare genetic thyroid disorder affecting over 1,000 US patients. Egetis launched the drug in the US in October, and about 60 US patients already take it through an early-access programme across 17 clinics. Management targets over $300 million in peak annual sales, but commercial spending will reduce profit per share excluding one-offs in the first year and push net debt to 2.7 times annual cash profit.
What to watch: tender offer acceptance by the December 18 deadline, which requires 90% of Egetis shares, alongside 2027 profit dilution once the deal closes.
🐻 Bear Case
Pharmacy Bottlenecks Trigger a Second Cortrophin Cut
Cortrophin Gel, an injectable hormone treatment for autoimmune and inflammatory flare-ups, is ANI's main growth engine. In June, chief executive Nikhil Lalwani expanded the rare-disease sales force by 50%, to about 180 reps, to pitch the drug for acute gout flares. New gout cases doubled from the second quarter and new prescribers rose about 67%, while existing specialties hit record new cases in October.
- Third-quarter Cortrophin Gel revenue: $138.7 million, missing the $143–153 million plan set last quarter
- Full-year Cortrophin Gel outlook: cut by $40 million at the middle of the range to $480–500 million, the second cut in two quarters
- Selling, general and administrative expenses excluding one-offs: $84.2 million, up 32.4% from a year ago and up 1.0 percentage point of revenue to 28.9%
- Implied fourth-quarter Cortrophin Gel revenue: $159.1 million at the middle of the range (+42.8% from a year ago and +14.8% from the third quarter) by our math
Despite the jump in prescriptions, filled orders lagged "due to capacity constraints in the Company’s specialty pharmacy network". ANI is adding pharmacies and patient support staff "to accelerate the conversion of strong demand into patients on therapy". Even after the $40 million cut, the new plan requires a 14.8% fourth-quarter jump by our math, well above last year's 9.4% fourth-quarter step.
What to watch: fourth-quarter Cortrophin Gel revenue against the $149–169 million range implied by the full-year plan. Falling short of a 10% sequential increase would show that gout prescriptions are converting into revenue at a lower rate than older specialties.
Risks this quarter didn't answer
Five standing concerns around pricing, prescription tracking, governance and legal exposure had no new numbers in the earnings release or presentation.
- Insurance restrictions and rebates on Cortrophin Gel: not disclosed in the release; management has previously declined to give net pricing details on competitive grounds.
- Gap between third-party prescription tracking data and reported Cortrophin revenue: not addressed in the release, though specialty pharmacy bottlenecks may explain part of the lag.
- Revenue per gout patient: gout flares use fewer vials per patient than chronic conditions, and the release did not quantify gout's dollar share of third-quarter sales.
- Related-party payments to entities linked to operating chief Muthusamy Shanmugam: not in the release; the quarterly Form 10-Q filing's related-party footnote will update the second quarter's $9.2 million figure.
- Pending lawsuits on ranitidine, Harmony patents and Acella: not in the release; the Form 10-Q legal proceedings footnote will provide the status of the October ranitidine trial.
👓 Other Themes
Buyback Starts Before Deal Borrowing
After buying no shares on the open market in the second quarter, ANI spent $7.5 million to repurchase 102,492 shares in the third quarter and another $12.5 million on 173,143 shares through November 2. That brings total buybacks to $20.0 million of its $100.0 million authorization, just as the company prepares to borrow up to $300 million from JPMorgan Chase to help fund the Egetis acquisition.
💲 Other KPIs
Cash generated from operations rose to $83.8 million in the third quarter, up from $56.7 million in the second quarter and $58.4 million in the first, bringing the nine-month total to $198.8 million. That lifted unrestricted cash to $420.8 million against $616.9 million of principal debt, leaving $196.1 million of net debt by our math before the Egetis deal.
Money owed by customers for delivered drugs rose 20.5% from a year ago by our math, growing slower than the 27.6% increase in third-quarter revenue. That shows customer collections kept pace with shipments across both the rare-disease and generics businesses.
Sales of older branded drugs fell 6.5% from a year ago to $10.0 million on lower demand for certain products. The shrinkage slowed from a 10.5% drop in the second quarter and a 50.9% drop in the first quarter, and the division now makes up just 3.4% of company revenue.
🔮 Guidance
Cut at the middle of the range. ANI narrowed the full-year sales plan, trimming the middle of the range by $5 million to $1,105 million, or 25.1% growth. By our math, that leaves $310.7 million for the fourth quarter (+25.8% from a year ago vs +27.6% this quarter). It is the first reduction after a $25 million raise in the first quarter and a hold in the second.
Cut. The drugmaker lowered its flagship product plan by $40 million at the middle of the range, to 40.9% growth, after specialty pharmacy bottlenecks slowed third-quarter dispensing. By our math, the new range still requires $159.1 million in the fourth quarter (+42.8% from a year ago and +14.8% from the third quarter). This is the second straight cut: $0M, -$27.5M, -$40.0M.
Raised. Management lifted the eye-implant outlook by $2 million at both ends, to 10.1% growth at the middle of the range, after holding it unchanged for two quarters. By our math, that leaves $22.3 million for the fourth quarter, flat with the third quarter and up 12.2% from a year ago.
Raised. Carey lifted the bottom of the cash profit range by $5 million, moving the middle up $2.5 million to $295 million, or 28.4% growth. By our math, that leaves $77.1 million for the fourth quarter, up 18.0% from a year ago against 39.8% in the third quarter, as gout sales-force costs weigh against lower Cortrophin sales. Moves this year: +$10.0M, $0M, +$2.5M.
Raised. The middle of the profit-per-share plan rose $0.10 to $9.54, or 20.9% growth, now factoring in 2026 share buybacks across an unchanged 21.5–21.8 million share count range. By our math, that leaves $2.58 per share for the fourth quarter, up 10.7% from a year ago. Moves this year: +$0.355, $0.00, +$0.10.
Raised. The middle of the full-year gross margin plan rose 0.25 percentage points to 60.65% as high-margin Harmony royalties and generic drugs took a larger share of sales than royalty-bearing Cortrophin Gel. Because nine-month gross margin excluding one-offs was 61.8%, the full-year target points to about 57.8% in the fourth quarter by our math.
Raised. ANI lifted its expected GAAP tax rate by 1 percentage point after recording a 28.3% tax rate in the third quarter and 29.3% over the first nine months. The company continues to use a flat 26% tax rate when calculating profit per share excluding one-offs.
❓ Key Questions
How quickly will new specialty pharmacies clear the Cortrophin backlog?
Cortrophin Gel missed its third-quarter target by $9.3 million at the middle of the range and took a $40 million full-year cut because specialty pharmacies could not process prescriptions fast enough. Investors need to know how many pharmacies are being added and when dispensing catches up.
What is the average revenue per gout patient on Cortrophin?
New gout cases doubled from the second quarter and new prescribers rose 67%, yet Cortrophin Gel revenue rose 18.4% sequentially. Because acute gout flare patients use fewer vials than chronic patients, the dollar value of a gout case determines whether the 180-rep sales force pays off.
How much will the Egetis launch reduce 2027 profit?
ANI plans to spend $434 million in enterprise value and borrow up to $300 million for Egetis, stating that commercial launch costs for EMCITATE will reduce profit per share excluding one-offs in Year 1. Management did not disclose the size of the 2027 commercial expense or interest bill.
Did related-party payments to Esjay and Nuray stay elevated?
In the second quarter, payments to entities linked to operating chief Muthusamy Shanmugam more than doubled to $9.2 million. Because the earnings release does not include footnote disclosures, investors must check the third-quarter Form 10-Q to see if those cash outflows continued.